Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL
Jae Park, MD, discusses the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.
Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia (ALL).
Patients with low lymphocyte counts after chemotherapy or allogeneic stem cell transplantation could benefit from off-the-shelf CAR T-cell products as collecting T cells can be challenging, says Park.
Moreover, patients may experience disease progression during the 3 to 4-week period of T-cell generation that may be mitigated by an off-the-shelf option, concludes Park.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
